Lynch Regenerative Medicine: Two Inds - Nov 18

Share this article
Spread the word on social media
The Story
Lynch Regenerative Medicine, LLC announced FDA authorization of two new Investigational New Drug applications for investigator-initiated trials of injectable rhPDGF-BB. The studies will evaluate facial skin quality and treatment of infraorbital hollowing, but the announcement did not establish FDA approval for either use.
No stock ticker, share price, trial enrollment, or timeline was provided, limiting immediate valuation analysis.
Why It Matters For Your Portfolio
- Two IND authorizations broaden the company’s clinical investigation into two aesthetic applications, creating potential milestones for investors to track.
- The trials are investigator-initiated, so progress and results depend on trial execution. Enrollment, timelines, costs, and financing needs were not disclosed.
- IND authorization allows clinical investigation, but it is not proof of safety or efficacy, nor marketing approval. Unfavorable clinical findings remain a key risk.
- Initiation and progress updates, enrollment and study timelines, and eventual safety and efficacy data are potential catalysts. These disclosures could inform valuation, but their timing is unknown.
The Trade
Growth-oriented investors following regenerative aesthetics may want to monitor trial execution and subsequent clinical disclosures, while recognizing the early-stage risks. The announcement supplies no share-price data or specific schedule, so there is no confirmed near-term date or price level to assess.
Investors can evaluate future updates against trial progress, enrollment, costs, and safety and efficacy findings. This report is informational and does not recommend buying, selling, or holding any security.